Patrick Daly

Cancer Nursing Today nonprod

In a study published in <a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.14874" target="_blank" rel="noopener">Clinical Transplantation</a>, researchers evaluated the impact of vitamin D deficiency (VDD) on hematopoietic stem cell transplantation (HSCT) outcomes in patients with thalassemia major (TM).The authors noted studies on this topic have reached conflicting conclusions due to patient heterogeneity. Based on their data, the authors suggested low vitamin D3 levels prior to HSCT were associated with significant risk for acute graft-versus-host disease (aGVHD).The investigators examined potential associations between VDD presence prior to HSCT and outcomes after HSCT in a &ldquo;relatively homogenous&rdquo; group of patients with TM. All participants had received identical treatment for TM prior to undergoing transplant, as well as the same conditioning and GVHD prophylaxis regimens.Researchers administered vitamin D 400-800 IU per day for the 6 months following HSCT, including in patients with normal vitamin D3 levels at baseline. Reportedly, patients with VDD prior to HSCT showed an increased rate of aGVHD after transplantation, particularly patients who received a peripheral blood stem cell-sourced graft.The study&rsquo;s authors did note that low vitamin D3 levels prior to HSCT did not show any associations with outcomes, including engraftment, viral infections, alloimmunization, chronic GVHD, length of hospitalization, and transfusion independence.&ldquo;All patients with TM should be screened for VDD before HSCT,&rdquo; the authors closed, &ldquo;and every effort should be made to supplement vitamin D before the transplant in VDD patients.&rdquo;Read More: <a href="https://cancernursingtoday.com/post/tacrolimus-concentration-variability-and-hsct-outcomes">Tacrolimus Concentration Variability and HSCT Outcomes</a>

Vitamin D Deficiency Impacts Graft-Versus-Host Disease Outcomes

GVHD

Vitamin D Deficiency before HSCT was associated with increased rate of aGVHD in patients with thalassemia major.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe